What systemic therapy would you use in patients with gastric cancer who had a relapse after Durva-FLOT (MATTERHORN regimen)?  

In the rapidly evolving era of more intensive perioperative therapy, the FLOT-durvalumab combination is quickly becoming the standard for good-performance patients who can tolerate triplet chemotherapy and have no contraindications to immunotherapy. What to do after recurrence will depend in part o...